Mariner
LCTX icon

Mariner’s Lineage Cell Therapeutics LCTX Stock Holding History

Mariner’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.8K Sell
12,514
-584
-4% -$985 ﹤0.01% 3491
2025
Q4 		$21.9K Buy
13,098
+1,903
+17% +$3.29K ﹤0.01% 3482
2025
Q3 		$18.9K Sell
11,195
-1,778
-14% -$2.1K ﹤0.01% 3513
2025
Q2 		$11.8K Sell
12,973
-1,263
-9% -$749 ﹤0.01% 3449
2025
Q1 		$6.43K Sell
14,236
-606
-4% -$355 ﹤0.01% 3422
2024
Q4 		$7.46K Buy
14,842
+2
+0% +$1 ﹤0.01% 3372
2024
Q3 		$13.4K Hold
14,840
– – ﹤0.01% 3261
2024
Q2 		$14.8K Sell
14,840
-2,000
-12% -$2.21K ﹤0.01% 3121
2024
Q1 		$24.9K Buy
16,840
+2,000
+13% +$2.27K ﹤0.01% 3082
2023
Q4 		$16.2K Sell
14,840
-17,162
-54% -$18.8K ﹤0.01% 3008
2023
Q3 		$37.8K Buy
32,002
+28
+0.1% +$38 ﹤0.01% 2796
2023
Q2 		$45.1K Buy
31,974
+18,134
+131% +$25.1K ﹤0.01% 2725
2023
Q1 		$21K Sell
13,840
-44
-0.3% -$61 ﹤0.01% 2723
2022
Q4 		$16K Sell
13,884
-343
-2% -$432 ﹤0.01% 2697
2022
Q3 		$16K Buy
+14,227
New +$20.9K ﹤0.01% 2397
2019
Q3 		– Sell
-60,295
Closed -$66K – 887
2019
Q2 		$66K Buy
+60,295
New +$69.5K ﹤0.01% 1090

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mariner's LCTX Position: Q1 2026 in Review

Mariner reduced its Lineage Cell Therapeutics (LCTX) stake by 4.5% in Q1 2026, selling an estimated $985 and leaving 12,514 shares worth $19.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3491.

Mariner first reported a position in LCTX in Q2 2019 and has held it in 16 quarters since. The position peaked at $66K in Q2 2019. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • Mariner held 12,514 shares of Lineage Cell Therapeutics worth $19.8K as of Q1 2026.
  • Mariner sold 584 Lineage Cell Therapeutics shares in Q1 2026, an estimated $985.
  • Lineage Cell Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #3491 holding.
  • Mariner first reported a position in Lineage Cell Therapeutics in Q2 2019 and has held it in 16 quarters since.
  • Mariner's Lineage Cell Therapeutics position peaked at $66K in Q2 2019.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.